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Abstract
P1,P4-Diadenosine 5P-tetraphosphate (Ap4A) acts as an extracellular modulator through its interaction with
purinoceptors. Our laboratory has demonstrated the presence of an Ap4A receptor in cardiac tissue [1,2]. Due to the
rapid hydrolysis of ATP by cardiac membranes the relationship of ATP and Ap4A binding to purinoceptors on cardiac
membranes has not been characterized. In this communication we used two approaches to determine the relationship of
ATP to the Ap4A receptor. Radioligand binding carried out with [K-32P]Ap4A and adenosine 5P-O-{3-thiotriphosphate}
([Q-35S]ATPQS) demonstrates the presence of a single high affinity binding site for Ap4A and the presence of two binding sites
for ATPQS.
The second approach utilized immunoaffinity purified Ap4A receptor that was shown to be free of ATPase and Ap4Aase
activities. Non-radiolabeled Ap4A and ATPQS effectively inhibited photocrosslinking of [K-32P]8-N3Ap4A to the receptor
polypeptide while ATP was a much less effective inhibitor. Furthermore, on plasma membranes [K-32P]8-N3Ap4A
photocrosslinked to only a 50 kDa polypeptide. These data are consistent with Ap4A interacting with a homogeneous
population of receptors on cardiac plasma membranes but with ATP having a low affinity for the receptor. ß 1998 Elsevier
Science B.V. All rights reserved.
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1. Introduction
In recent years it has become increasingly clear
that adenylated dinucleotides act as extracellular
modulators of various biological processes. P1,P4-Di-
adenosine 5P-tetraphosphate (Ap4A) is one of the
most abundant and the best characterized adenylated
dinucleotide. Ap4A is co-stored with Ap3A, Ap5A
Ap6A and ATP in the dense secretory granules of
platelets [3,4]. In chroma⁄n cells, Ap4A, Ap5A,
Ap6A are co-stored with AMP, ADP, ATP and cat-
echolamines [5,6]. It has been estimated that follow-
ing localized release from platelets and chroma⁄n
cells, Ap4A could reach physiologically signi¢cant
concentrations. Furthermore, compared with ATP,
Ap4A has a relatively long half-life in whole blood
[7]. Thus, Ap4A is well suited for a role as an extra-
cellular modulator.
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Among the better characterized targets for extrac-
ellular Ap4A are cells of the vascular system. Ap4A
has been shown to modulate blood vessel tone [8^10],
induce the release of nitric oxide from endothelial
cells [11], prime respiratory burst and regulate apop-
tosis in neutrophils [12] and inhibit ADP-induced
platelet aggregation [13,14]. Additionally, in other
tissues Ap4A has been shown to promote catechol-
amine release [15], activate glycogen phosphorylase in
hepatocytes [16] and elicit smooth muscle contrac-
tions in vas deferens [17] and urinary bladder [18].
The biological e¡ects of Ap4A on cells have been
attributed to its interaction with cell surface recep-
tors where it induces calcium mobilization [19,20].
However, the nature of the receptor(s) in Ap4A
mediated signal transduction remains unclear. In liv-
er plasma membranes Ap4A appears to bind to a
single class of P2Y binding sites [21]. In vas deferens
and urinary bladder Ap4A interacts with P2X recep-
tors [17,18]. However, in brain synaptosomes Ap4A
interacts with two classes of binding sites: a high
a⁄nity site which appears to be speci¢c for adeny-
lated dinucleotides (P2D) and a second low a⁄nity
site [22].
Our laboratory has demonstrated in partially pu-
ri¢ed cardiac membrane homogenates that Ap4A in-
teracts with a P2D receptor and that this receptor
undergoes an activation step which enhances only
Ap4A binding [1,2,23]. In addition, investigators
have recently demonstrated in cardiac tissue the ex-
istence of P2X and P2Y purinoceptors [24,25]. These
data suggest that Ap4A may interact with a hetero-
geneous population of receptors in cardiac tissue that
may consist of speci¢c dipurinoceptors and/or one or
more P2 purinoceptor subtypes. These considerations
led us to investigate the relationship of ATP and
Ap4A binding on puri¢ed plasma membranes. In
this communication we demonstrate that Ap4A inter-
acts with a homogeneous population of receptors on
cardiac plasma membranes while ATP does not bind
in appreciable amounts to the Ap4A receptor.
2. Materials and methods
2.1. Materials
Swiss mice were obtained from Charles River Lab-
oratories. The animals were housed in an animal
facility maintained with a photoperiod of 15L:9D
and room temperatures of 22^25‡C. [K-32P]ATP
(3000 Ci/mmol) and [32P]inorganic phosphate (3000
Ci/mmol) were purchased from DuPont New Eng-
land Nuclear. [Q-35S]ATPQS (1000 Ci/mmol) was pur-
chased from ICN. All nucleotides and goat serum
were purchased from Sigma. En3Hance Spray was
obtained from DuPont New England Nuclear. A⁄-
Gel Hz resin, and Kaleidoscope molecular weight
markers were purchased from Bio-Rad. DC-Plastik-
folien 20U20 cm PEI-Cellulose F plates were pur-
chased from EM Science. All other reagents were
of analytical reagent grade or better.
2.2. Synthesis and puri¢cation of [K-32P]Ap4A and
[K-32P]8-N3Ap4A
[K-32P]Ap4A and [K-32P]8-N3Ap4A were synthe-
sized and puri¢ed with yields of about 45% as
described [1]. Purity was greater than 95% as deter-
mined by thin-layer chromatography and auto-
radiography.
2.3. Puri¢cation of cardiac plasma membranes
Mouse cardiac plasma membranes were puri¢ed as
described [26]. Brie£y, four mouse hearts were sus-
pended in 40 vols. of HEPES bu¡ered saline with
glucose and potassium (HBSGK), which contained
20 mM HEPES (pH 7.4), 150 mM NaCl, 2 mM
glucose, 3 mM KCl and 1 mM CaCl2 in addition
to 0.1% Triton X-100. The suspended hearts were
minced and homogenized with a Dounce homogeniz-
er. After homogenization, the samples were ¢ltered
through cheesecloth and centrifuged at 12 000Ug for
10 min at 4‡C. The supernatant was centrifuged at
100 000Ug for 90 min at 4‡C and the pellet was
resuspended in 0.5 ml of HBSGK bu¡er containing
0.1% Triton X-100 and 8.5% sucrose (postmitochon-
drial membrane).
Plasma membranes were separated from sarcoplas-
mic reticulum by sucrose density centrifugation of
the postmitochondrial membrane fraction. Linear su-
crose gradients were formed using 19.5 ml of 62.8%
sucrose in HBSGK bu¡er containing 0.1% Triton
X-100 and 9.5 ml of 8.5% sucrose HBSGK bu¡er
containing 0.1% Triton X-100. The samples were
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centrifuged in a VTi50 rotor at 95 416Ug for 6 h at
4‡C. The plasma membrane fraction was identi¢ed
using membrane marker enzymes as described [26].
The plasma membranes were stored in aliquots at
380‡C for up to 3 months without loss of Ap4A
binding activity.
2.4. Stability of Ap4A, ATP, ATPQS and K,L-MeATP
during binding assays
All experiments were performed in triplicate and
repeated three times. Assays were performed in 0.1 ml
reaction mixtures. Reaction mixtures contained
either 0.9 WM [K-32P]ATP (speci¢c activity 5000^
6000 cpm/pmole), 0.5 WM [K-32P]Ap4A (speci¢c ac-
tivity 5000^6000 cpm/pmole), 0.6 WM [Q-35S]ATPQS
(speci¢c activity 30 000^40 000 cpm/pmole) or
0.9 WM [2,8-3H]K,L-MeATP (speci¢c activity 3000^
4000 cpm/pmole) in 67 mM Tris-HCl, pH 7.7 and
0.1 mM MgCl2 (assay bu¡er). The reactions were
initiated by the addition of 2.5 Wg of plasma mem-
branes and incubated for various times at 20‡C.
After incubation, 2 Wl of the reaction mixture along
with 2 Wl non-radiolabeled standards (25 mM of
Ap4A, ATP, ADP, AMP) and [32P]inorganic phos-
phate (1.0U105 cpm) were spotted on DC-Plastikfo-
lien PEI-Cellulose F Plates (TLC plates).
For experiments involving [K-32P]ATP or [K-
32P]Ap4A, TLC plates were developed in 1 M LiCl
as described [27]. After development, plates were
dried and autoradiography was carried out at
380‡C for 4^5 h using Kodak X-OMATAR X-ray
¢lm and Cronex Lighting Plus intensifying screens.
TLC chromatography with [Q-35S]ATPQS was accom-
plished using 0.3 M K2HPO4, pH 7.0. Autoradiog-
raphy was carried out at 380‡C for 5 h after spray-
ing TLC plates with En3Hance Spray. TLC
chromatography with [2,8-3H]K,L-MeATP was car-
ried out in 1 M LiCl as described [27]. Autoradiog-
raphy was carried out at 380‡C for 72^96 h after
spraying the TLC plates with En3Hance Spray.
Densitometer tracings of autoradiographs were
obtained using a Pharmacia LKB UltraScan XL En-
hanced Laser Densitometer connected to an IBM
486 Personal Computer with LKB GelScan XL (ver-
sion 2.1) software. Percentage of nucleotide hydrol-
ysis was calculated from the relative percentage of
total absorbance units (A533Umm2).
2.5. Radionucleotide binding assays
All experiments were performed in triplicate and
repeated at least three times. Ap4A binding assays
were performed as described [28]. Binding assays
were performed in 0.1 ml reaction mixtures. Each
reaction mixture contained 67 mM Tris-HCl, pH
7.7 and 0.1 mM MgCl2 (assay bu¡er) and 0.5 WM
[32P]Ap4A (5000^6000 cpm/pmole). Reactions were
initiated by the addition of 2.5 Wg of plasma mem-
brane and incubated for 15 min at 20‡C. Membranes
were collected on Whatman R/A glass ¢ber discs,
washed three times with 3 ml portions of 67 mM
Tris-HCl, pH 7.7, 0.1 mM MgCl2. The discs were
dried and counted in 5 ml of a toluene-based scintil-
lation £uid. Blanks contained all components except
membranes.
ATPQS binding was assayed as above except using
0.9 WM [Q-35S]ATPQS (5000^6000 cpm/pmole). Due
to non-speci¢c binding of [Q-35S]ATPQS to the glass
¢ber discs, the glass ¢ber discs were presoaked in
67 mM Tris-HCl (pH 7.7) and 50 mM sodium py-
rophosphate. Membranes were then collected on
these discs, washed three times with 3 ml portions
of 67 mM Tris-HCl, pH 7.7, 0.1 mM MgCl2 and
10 WM sodium pyrophosphate. The discs were dried
and counted in 5 ml of a toluene-based scintillation
£uid. Blanks contained all components except mem-
branes.
2.6. Computer analysis of binding data
Saturation binding curves were ¢tted by a
weighted non-linear least square method directly to
cpm data and analyzed by the program LIGAND
[29]. For displacement experiments, all displacement
data were ¢tted simultaneously by LIGAND. This
approach involves a multistep weighted non-linear
least squares analysis of single homologous, then het-
erologous displacement data for each radioligand
and ¢nally a simultaneous analysis of all displace-
ment data. This approach yields a more reliable es-
timation of equilibrium binding parameters for mul-
tiple ligands [29]. One, two, and three site models
were investigated and compared by the F-test with
the more complex model accepted only if there was
a signi¢cant reduction in the sum of squares
(P6 0.05).
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2.7. Immunoa⁄nity puri¢cation of the Ap4A receptor
The A⁄-Gel Hz Immunoa⁄nity Kit (Bio-Rad)
was used to generate an anti-Ap4A receptor mono-
clonal antibody (mAb TL4) a⁄nity column. Mono-
clonal antibody TL4 which blocks Ap4A binding to
its cardiac membrane receptor was isolated as de-
scribed [23]. Monoclonal antibody TL4 (4^5 mg)
was exchanged into the coupling bu¡er (pH 5.5) us-
ing an Econ-Pac 10DG desalting column. Monoclo-
nal antibody TL4 carbohydrates were then oxidized
in sodium m-periodate (20.8 mg/ml) by incubating
the sample in the dark for 1 h at room temperature
(1:10 NaIO4 :mAb TL4 v/v) followed by desalting
through an Econ-Pac 10DG desalting column. Oxi-
dized mAb TL4 was coupled to 3 ml of A⁄-Gel Hz
resin for 24 h at room temperature in coupling buf-
fer. The mAb TL4 coupled resin (A⁄-Gel Hz) was
washed with 3 bed vols. of PBS (0.145 M NaCl,
38 mM Na2HPO4, 11 mM NaH2PO4, pH 7.0) con-
taining 0.5 M NaCl and then stored in TBS (50 mM
Tris-HCl and 150 mM NaCl, pH 7.4) containing
0.02% NaN3.
To immunoa⁄nity purify the Ap4A receptor the
mAb TL4 coupled A⁄-Gel Hz resin was blocked by
¢rst washing with TBS containing 5% goat serum
followed by incubating with TBS containing 20%
goat serum overnight at 4‡C. Postmitochondrial
membrane pellets were resuspended in TBS contain-
ing 1% SDS to give a protein concentration of 2 mg/
ml. The sample was denatured by boiling for 25 min
and then su⁄cient TBS was added to reduce the SDS
to 0.2%. The sample was centrifuged at 16 000Ug for
30 min and the supernatant incubated overnight at
4‡C with mAb TL4 coupled A⁄-Gel Hz resin which
has been blocked with goat serum. This mixture was
packed into a 1.2 cm by 14.5 cm column and washed
with 25 ml of TBS. The unbound protein was washed
o¡ with 10 mM KH2PO4, pH 6.8 until the A280 was
below 0.01. The bound protein was eluted with
200 mM glycine, pH 2.5 in 2.0 ml fractions and the
pH of each fraction was neutralized by the addition
of 175 Wl of 1.5 mM Tris-HCl, pH 8.8. The protein
eluted as a single A280 peak and the three tubes with
highest absorbance were pooled, dialyzed against
three changes of 67 mM Tris-HCl (pH 7.7), concen-
trated by Centricon-10 (Amicon), and stored at
320‡C. A protease inhibitor cocktail containing leu-
peptin, antipain, chymostatin, pepstatin each at a
¢nal concentration of 1 Wg/ml and 2 mM phenyl-
methylsulfonyl £uoride was included in all bu¡ers
used in the immunoa⁄nity puri¢cation of the
Ap4A receptor.
2.8. Photolabeling of the immunoa⁄nity puri¢ed
receptor
All operations involving 8-azido nucleotides were
performed under subdued light. Reaction mixtures
contained 5 Wg of immunoa⁄nity puri¢ed receptor
in 30 Wl of assay bu¡er plus [K-32P]8-N3Ap4A (spe-
ci¢c activity 1200^1800 cpm/pmole). These reaction
mixtures were incubated for 30 min at 20‡C in the
dark. The samples were irradiated at 4‡C using a
short-wavelength UV lamp at 254 nm and a dose
rate of 300 WW/cm2 for 60 s. SDS-PAGE and West-
ern transfer were performed as described [1]. Auto-
radiography was carried out at 380‡C for 14^24 h
using Kodak X-OMATAR X-ray ¢lm and Cronex
Lighting Plus intensifying screens. Densitometer
analysis of autoradiographs was performed as de-
scribed above.
2.9. Protein determination
Protein concentrations were determined by the
Bradford method [30].
3. Results
3.1. Stability of Ap4A and ATP during binding assays
Prior to performing binding experiments it is nec-
essary to ensure that the radiolabeled ligands are not
hydrolyzed by plasma membrane nucleases under
binding conditions. As shown in Fig. 1, [K-32P]ATP
is rapidly hydrolyzed with only 64.9% and 33.3% of
the radiolabel remaining as ATP after 3 and 15 min
of incubation, respectively. In contrast, [K-32P]Ap4A
and [Q-35S]ATPQS were signi¢cantly more stable with
80% and 92% of the radiolabel remaining intact after
15 min, respectively (Fig. 1). Furthermore, essentially
none of the [3H]K,L-MeATP was hydrolyzed after
60 min (data not shown). Control samples contained
all assay components except plasma membranes and
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were incubated for 60 min prior to TLC. No degra-
dation of the radiolabeled nucleotides was detected
in these samples. These data are consistent with pu-
ri¢ed cardiac plasma membranes containing nucle-
ases which rapidly hydrolyze ATP while hydrolyzing
Ap4A, ATPQS and K,L-MeATP at signi¢cantly slow-
er rates.
3.2. Binding characteristics of Ap4A and ATPQS
to cardiac plasma membranes
Due to the rapid hydrolysis of ATP, this ligand
was not used in binding studies. The binding of
0.5 WM [K-32P]Ap4A to cardiac membranes was lin-
ear with protein concentrations from 1.0 Wg to 4.0 Wg
while the binding of 0.9 WM [Q-35S]ATPQS was linear
with protein concentrations from 1.0 Wg to 25.0 Wg
(data not shown). Ap4A binding to 2.5 Wg of plasma
membranes reached a plateau after 12 min. Longer
incubations up to 30 min did not signi¢cantly in-
crease the maximal amount of [K-32P]Ap4A bound
(data not shown). [Q-35S]ATPQS binding to 2.5 Wg
cardiac plasma membranes reached a plateau after
10 min. Incubations up to 30 min did not signi¢-
cantly increase the maximal amount of [Q-35S]ATPQS
bound (data not shown). These results demonstrated
that binding equilibrium was attained within a time
where hydrolysis would not be a factor. All subse-
quent Ap4A and ATPQS binding experiments were
performed using 2.5 Wg of plasma membrane for
15 min at 20‡C.
3.3. Speci¢city of Ap4A and ATPQS binding to
cardiac plasma membranes
In an attempt to determine binding parameters for
Ap4A and ATPQS, binding experiments were per-
formed using a variable amount of either
[K-32P]Ap4A or [Q-35S]ATPQS and a ¢xed amount of
plasma membrane (Fig. 2). [K-32P]Ap4A binding pla-
teaued at 0.25 WM while [Q-35S]ATPQS plateaued at
0.6 WM. Binding data are displayed in the Scatchard
coordinate system and indicated a linear relationship
for Ap4A (Fig. 3A) which suggests that there is a
single binding site for Ap4A. Data analysis with the
program LIGAND is consistent with one class of
high a⁄nity binding sites for Ap4A with an apparent
receptor density (Bmax) of 66 pmoles mg31 of mem-
brane protein and an apparent Kd value of 0.05 WM
(Table 1). On the other hand, Scatchard analysis
Fig. 1. Time course of nucleotide hydrolysis by cardiac plasma
membranes. 2.5 Wg of plasma membranes were incubated at
20‡C in a ¢nal volume of 0.1 ml of binding bu¡er for the indi-
cated times with 0.9 WM [K-32P]ATP (speci¢c activity 5000^6000
cpm/pmole), 0.5 WM [K-32P]Ap4A (speci¢c activity 5000^6000
cpm/pmole) or 0.6 WM [Q-35S]ATPQS (speci¢c activity 30 000^
40 000 cpm/pmole) for the indicated times. After incubations,
2 Wl of the reaction mixture was spotted on TLC plates and
separated as described in Section 2. E, Ap4A; F, ATP; R,
ATPQS. The relative percentage was calculated from densitome-
ter tracings of autoradiographs as described in Section 2. The
results are expressed as averages of three di¡erent experiments
in triplicate (nine total data points). Error bars are shown as
standard deviations.
Fig. 2. [K-32P]Ap4A and [Q-35S]ATPQS binding to cardiac plas-
ma membranes. The binding assay is described in the text.
Varying concentrations of [K-32P]Ap4A (speci¢c activity 6000^
9000 cpm/pmole) or [Q-35S]ATPQS (speci¢c activity 6000^9000
cpm/pmole) were incubated with 2.5 Wg of plasma membranes
for 15 min at 20‡C. b, Ap4A; E, ATPQS. The results are ex-
pressed as averages of three di¡erent experiments performed in
triplicate (nine total data points). Error bars are shown as
standard deviations.
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showed a non-linear relationship for ATPQS (Fig.
3B) which suggests there are either two classes of
binding sites for ATPQS or there are both speci¢c
high a⁄nity binding sites and non-speci¢c binding
sites. When using the LIGAND program the analysis
is dominated by high a⁄nity interactions. Due to the
weighted analysis, the apparent ATPQS Kd value has
an upper limit value of 0.03 WM for the high a⁄nity
site and an apparent Bmax of 99 pmoles mg31 of
membrane protein (Table 1).
Equilibrium binding parameters were also deter-
mined by performing homologous and heterologous
competition studies of [K-32P]Ap4A and [Q-35S]ATPQS
binding using non-radiolabeled Ap4A, ATPQS, K,L-
MeATP and adenosine. The ability of non-radiola-
beled Ap4A, ATPQS and K,L-MeATP to inhibit
[K-32P]Ap4A binding is presented in Fig. 4A. Varia-
ble amounts of non-radiolabeled nucleotides and a
¢xed amount of [K-32P]Ap4A were incubated with
plasma membranes for 15 min at 20‡C. As expected,
non-radiolabeled Ap4A e¡ectively competes with
[K-32P]Ap4A for binding sites. Non-radiolabeled
ATPQS competed as e¡ectively as did non-radiola-
beled Ap4A. However, the P2X agonist, K,L-MeATP,
was not an e¡ective competitor of [K-32P]Ap4A bind-
ing by at least two orders of magnitude.
The ability of non-radiolabeled Ap4A, ATPQS,
K,L-MeATP to compete for [Q-35S]ATPQS binding is
presented in Fig. 4B. Variable amounts of non-
radiolabeled nucleotides and a ¢xed amount of
[Q-35S]ATPQS were incubated with plasma mem-
branes for 15 min at 20‡C. Non-radiolabeled ATPQS,
as expected, e¡ectively competes for [Q-35S]ATPQS
binding sites. However, non-radiolabeled Ap4A was
not an e¡ective competitor of [Q-35S]ATPQS bind-
ing. In fact 1 mM Ap4A inhibits only 60% of
[Q-35S]ATPQS binding. This is in contrast to the re-
verse experiment in which non-radiolabeled ATPQS
e¡ectively inhibited [K-32P]Ap4A binding (Fig. 4A).
K,L-MeATP was also not an e¡ective competitor of
[Q-35S]ATPQS binding with only 60% inhibition at a
concentration of 1 mM. These data are consistent
with the presence of a second class of low a⁄nity
binding sites for ATPQS which is not e¡ectively com-
peted for by Ap4A or K,L-MeATP.
The P2X purinoceptor agonist K,L-MeATP did not
e¡ectively compete with either [K-32P]Ap4A (Fig. 4A)
or [Q-35S]ATPQS (Fig. 4B) binding. In addition ad-
enosine did not compete with either [K-32P]Ap4A or
[Q-35S]ATPQS binding at concentrations up to 10 mM
(data not shown). These data are consistent with
neither the high nor low a⁄nity binding sites being
a P2X or P1 receptor.
Computer analyses of all homologous and heterol-
ogous displacement studies were ¢tted simultane-
ously with LIGAND and predicted the presence of
one high a⁄nity binding site for both Ap4A and
ATPQS and an additional low a⁄nity binding site
for ATPQS. At the high a⁄nity binding site the ap-
parent Kd values for Ap4A and ATPQS are 0.08 WM
and 0.04 WM, respectively (Table 1). Non-speci¢c
Fig. 3. Scatchard analysis of [K-32P]Ap4A and [Q-35S]ATPQS
binding to cardiac plasma membranes. Experiments were per-
formed as described in the legend of Fig. 2. The data were ana-
lyzed by LIGAND [29] and are displayed as Scatchard plots.
(A) Scatchard analysis of Ap4A binding data. The solid line
represents the Scatchard parameters generated from linear re-
gression analysis. (B) Scatchard analysis of ATPQS binding
data. The dashed line represents the line generated by the appa-
rent Kd derived from LIGAND after subtracting non-speci¢c
binding.
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binding ratios of 0.001 and 0.0007 were calculated
for Ap4A and ATPQS, respectively, indicating that
less than 0.1% of the total high a⁄nity binding was
due to non-speci¢c interactions. The apparent Kd
value for the low a⁄nity ATPQS site is 1.0 WM (Table
1); however, the non-speci¢c binding ratio of 0.012 is
relatively high compared to those for the high a⁄nity
site. These data are consistent with Ap4A and ATPQS
binding to the same high a⁄nity site on cardiac plas-
ma membranes.
3.4. Identi¢cation of the Ap4A receptor by
photocrosslinking [K-32P]8-N3Ap4A to plasma
membranes
To identify the Ap4A receptor, 5 Wg of plasma
membranes were incubated with [K-32P]8-N3Ap4A
for 30 min at 20‡C prior to UV crosslinking. SDS-
PAGE followed by Western transfer and autoradiog-
raphy revealed [K-32P]8-N3Ap4A photolabeling of a
50 kDa and a smaller amount of a 30 kDa polypep-
tide (Fig. 5). Since we have previously shown that the
30 kDa polypeptide is a consequence of artifactual
receptor proteolysis [26], these data are consistent
with Ap4A binding to a 50 kDa polypeptide on pu-
ri¢ed cardiac plasma membranes.
The hydrolysis of ATP by cardiac plasma mem-
branes prevented the use of ATP in radioligand bind-
ing studies. In an attempt to determine the interac-
tions of ATP with the cardiac Ap4A receptor, studies
using immunoa⁄nity puri¢ed Ap4A receptor were
performed. The Ap4A receptor polypeptide was im-
munoa⁄nity puri¢ed with an anti-Ap4A receptor
mAb (mAb TL 4) that we have raised against the
mouse cardiac receptor [23]. The immunoa⁄nity pu-
ri¢ed receptor was photolabeled with varying con-
centrations of [K-32P]8-N3Ap4A, followed by SDS-
PAGE, Western transfer and autoradiography. As
shown in Fig. 6, photolabeling with [K-32P]8-
N3Ap4A was linear for concentrations of 5^20 WM
and reached a plateau at 20 WM.
The ability of non-radiolabeled Ap4A, ATPQS and
ATP to inhibit [K-32P]8-N3Ap4A photocrosslinking
to puri¢ed polypeptide fractions is shown in Fig. 7.
Ligand speci¢city of the Ap4A receptor was deter-
mined by incubating variable amounts of non-radio-
labeled nucleotides and a ¢xed amount of [K-32P]8-
N3Ap4A prior to UV crosslinking, SDS-PAGE,
Western transfer and autoradiography. As expected
both Ap4A and ATPQS e¡ectively inhibit [K-32P]8-
N3Ap4A crosslinking to the receptor polypeptides.
However, ATP is signi¢cantly less e¡ective at com-
peting for [K-32P]8-N3Ap4A (Fig. 7). The estimated
IC50 values for ATPQS, Ap4A and ATP are 56 WM,
158 WM and 2500 WM, respectively. Higher concen-
trations of Ap4A and ATPQS were required for com-
peting with [K-32P]8-N3Ap4A photocrosslinking (Fig.
7) than with [32P]Ap4A binding to plasma mem-
branes (Fig. 4). The higher concentration of non-
photoactive ligand that is required to inhibit photo-
labeling can be explained on the basis of reversible
binding of the non-photoactive ligand and the cova-
Table 1
Kd values for nucleotide binding to cardiac plasma membranes
Nucleotide Scatchard analysisa Competition analysisb
Kd high a⁄nity site (WM) Kd high a⁄nity site (WM) Kd low a⁄nity site (WM)
Ap4A 0.05 0.08 ^
ATPQS 0.03c 0.04 1.0
K,L-MeATP ndd 3.0 ^
a2.5 Wg of plasma membranes were incubated with varying amounts of either [K-32P]Ap4A (speci¢c activity 6000^9000 cpm/pmole) or
[Q-35S]ATPQS (speci¢c activity 6000^9000 cpm/pmole) in a ¢nal volume of 0.1 ml as described in the legend of Fig. 2. Saturation bind-
ing curves were ¢tted directly to raw cpm data and analyzed by the program LIGAND as described in the text.
b2.5 Wg of plasma membranes were incubated with either 0.5 WM [K-32P]Ap4A (speci¢c activity 6000^9000 cpm/pmole) or 0.9 WM
[Q-35S]ATPQS (speci¢c activity 6000^9000 cpm/pmole) and varying amounts of competing non-radiolabeled ligand (0.4 nM^1.0 mM) in
a ¢nal volume of 0.1 ml as described in the legend of Fig. 4. Data from all homologous and heterologous displacement experiments
were simultaneously ¢tted and analyzed by the program LIGAND as described in the text.
cUpper limit Kd value for the high a⁄nity site.
dEquilibrium binding parameters were not determined by this method.
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lent binding of the photoactive ligand [31]. In addi-
tion, similar observations have been made by other
investigators who found that excess cAMP and
Ap4A were required to inhibit photoincorporation
of 8-N3-cAMP and 8-N3Ap4A, respectively [31,32].
To ensure that the immunoa⁄nity puri¢ed Ap4A
receptor did not contain Ap4A hydrolyases or AT-
Pases, immunoa⁄nity puri¢ed receptor was incu-
bated with [32P]Ap4A, [Q-32P]ATP or [Q-35S]ATPQS
for 30 min at 20‡C. Aliquots were subjected to
TLC followed by autoradiography. Greater than
90% of radiolabeled [32P]Ap4A, [Q-32P]ATP and [Q-
35S]ATPQS co-migrates with non-radiolabeled
Ap4A, ATP and ATPQS, respectively (data not
shown). Furthermore, the design of [K-32P]8-N3Ap4A
is such that no likely degradation products can con-
tain both radiolabel and photoactive azido group,
thus ensuring that any labeling is due to the intact
molecule. These data are consistent with Ap4A and
ATPQS speci¢cally interacting with the cardiac plas-
ma membrane Ap4A receptor but with ATP having a
low a⁄nity for this receptor.
4. Discussion
In di¡erent tissues and cell types Ap4A has been
shown to interact with P2Y, P2X, as well as P2D pu-
rinoceptors [1,2,17,18,21,22,24,25]. Furthermore, evi-
dence from physiological and molecular studies sug-
gests that a heterogeneous population of
purinoceptors exists within cardiac tissue [24,25].
However, the relationship of Ap4A to the various
purinoceptors in cardiac plasma membranes is not
clear. The work presented in this communication is
consistent with Ap4A and ATPQS interacting with a
homogeneous population of receptors on cardiac
plasma membranes and that ATP has a low a⁄nity
for the Ap4A receptor.
The presence of ectonucleotidases that rapidly hy-
Fig. 4. Inhibition of [K-32P]Ap4A and [Q-35S]ATPQS binding to
cardiac plasma membranes by unlabeled Ap4A, ATPQS and
K,L-MeATP. The binding assay is described in the text.
(A) 2.5 Wg of plasma membranes were incubated with 0.5 WM
[K-32P]Ap4A (speci¢c activity 6000^9000 cpm/pmole) and vary-
ing concentrations of non-radiolabeled ligand for 15 min at
20‡C. b, Ap4A; R, ATPQS; E, K,L-MeATP. (B) 2.5 Wg of plas-
ma membranes were incubated with 0.9 WM [Q-35S]ATPQS (spe-
ci¢c activity 6000^9000 cpm/pmole) and varying concentrations
of non-radiolabeled nucleotide for 15 min at 20‡C. b, Ap4A;
R, ATPQS; E, K,L-MeATP. Results are expressed as averages
of at least six experiments in duplicate (12 total data points).
Error bars are shown as standard deviations.
Fig. 5. SDS-PAGE and autoradiography of [K-32P]8-N3Ap4A
photolabeled cardiac plasma membrane. Plasma membrane was
isolated as described in the text. 5.0 Wg of plasma membrane
were incubated in 30 Wl of assay bu¡er with 1.2 nM [K-32P]8-
N3Ap4A (speci¢c activity 4.8U107 cpm/pmole) for 30 min at
20‡C prior to UV crosslinking and SDS-PAGE as described in
the text. Molecular weights are denoted by the arrows.
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drolyze ATP and adenylated dinucleotides may pre-
clude direct investigations into the action of these
nucleotides on many tissues and cells. Hulme and
Birdsall have suggested that greater than 75% of
the radioligand must remain intact to obtain reliable
equilibrium binding parameters [33]. Optimal bind-
ing conditions required a 15 min incubation at 20‡C
to obtain equilibrium. Following a 15 min incuba-
tion, 80.2%, 91.7%, 100% and 33.3% of the radio-
labeled Ap4A, ATPQS, K,L-MeATP and ATP mi-
grated with control standards, respectively (Fig. 1).
These data demonstrate that Ap4A, ATPQS, K,L-
MeATP meet the Hulme and Birdsall criteria, while
using ATP in receptor-ligand studies would be biased
by unknown concentrations of hydrolytic products.
Considering the rapid hydrolysis of ATP by car-
diac plasma membranes two synthetic ATP analogs
were selected for use in radioligand binding studies.
We chose ATPQS, a potent P2Y agonist [34], and K,L-
MeATP, a potent P2X agonist [18], to investigate
mononucleotide interactions with the Ap4A receptor
on cardiac plasma membranes. Homologous and het-
erologous competition studies carried out with
[K-32P]Ap4A and [Q-35S]ATPQS are consistent with
Ap4A interacting with only a single class of high
a⁄nity binding site while ATPQS interacts with this
same class of high a⁄nity sites and a second low
a⁄nity site (Fig. 4 and Table 1). Apparent Kd values
for the high a⁄nity site obtained from competition
studies for Ap4A and ATPQS are in good agreement
with the values obtained from Scatchard analysis
(Table 1). Computer curve-¢tting of both competi-
tion and Scatchard analysis is consistent with Ap4A
binding to a homogeneous population of receptors
on cardiac plasma membranes.
The use of multiple radioligands and two inde-
pendent methods for determining equilibrium bind-
ing parameters not only strengthens the notion of a
single high a⁄nity Ap4A receptor but also allows for
the observation of a two binding site model for
ATPQS. Although Ap4A and ATPQS both e¡ectively
competed for [K-32P]Ap4A binding, Ap4A only com-
peted with 60% of the total [Q-35S]ATPQS binding
(Fig. 4B). These data are consistent with the presence
of at least two binding sites for ATPQS on cardiac
plasma membranes.
The apparent Kd values of 0.03 and 0.04 WM for
ATPQS (Table 1) are similar to the values reported
for ATPQS binding to P2Y receptors on endothelial
Fig. 6. SDS-PAGE and autoradiography of [K-32P]8-N3Ap4A
photolabeled immunoa⁄nity puri¢ed Ap4A receptor 50 kDa
polypeptide. 5.0 Wg of immunoa⁄nity puri¢ed receptor were in-
cubated in 30 Wl of assay bu¡er with varying amounts of
[K-32P]8-N3Ap4A (speci¢c activity 1200^1800 cpm/pmole) for
30 min at 20‡C prior to UV crosslinking and SDS-PAGE as
described in the text. Photolabeling was detected by autoradio-
graphy and quanti¢ed by densitometry as described in the text.
Absorbance units are equal to A533Umm2. The results are ex-
pressed as an average of three di¡erent experiments in triplicate
(nine total data points). Error bars are shown as standard devi-
ations.
Fig. 7. Inhibition of [K-32P]8-N3Ap4A binding to the immu-
noa⁄nity puri¢ed Ap4A receptor 50 kDa polypeptide by unla-
beled Ap4A, ATPQS and ATP. 5.0 Wg of immunoa⁄nity puri-
¢ed receptor were incubated in 30 Wl of assay bu¡er with 25 WM
[K-32P]8-N3Ap4A (speci¢c activity 1200^1800 cpm/pmole) and
various concentrations of non-radiolabeled Ap4A, ATPQS, or
ATP for 30 min at 20‡C prior to UV crosslinking and SDS-
PAGE as described in the text. Photolabeling was detected by
autoradiography and quanti¢ed by densitometry as described in
the text. Absorbance units are equal to A533Umm2. E, Ap4A;
b, ATPQS; F, ATP. The results are expressed as an average of
three di¡erent experiments in triplicate (nine total data points).
Error bars are shown as standard deviations.
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membranes (0.01 WM) [35] and for ATPKS binding
to P2Y receptors on liver plasma membranes
(0.19 WM) [36,37]. Ap4A binds to a single class of
P2Y binding sites on liver plasma membranes with
an apparent Kd value (1.76 WM) [21] that is about
33-fold higher than the value we obtained from car-
diac plasma membranes (Table 1). On the other
hand, Ap4A appears to bind to two classes of bind-
ing sites on brain synaptosomes and chroma⁄n cells
with apparent Kd values of 0.1 nM and 0.08 nM for
the high a⁄nity sites and apparent Ki values of
0.57 WM and 0.13 WM for the low a⁄nity sites, re-
spectively [22,38]. These data suggest that there may
be heterogeneity of Ap4A binding sites in the various
tissues.
Competition studies indicate that Ap4A and
ATPQS have similar binding a⁄nities for the high
a⁄nity site while K,L-MeATP and adenosine were
ine¡ective competitors of either [K-32P]Ap4A or
[Q-35S]ATPQS. Other investigators have demonstrated
that ATPKS and K,L-MeATP bind to di¡erent P2Y
and P2X purinoceptors on brain synaptosomal mem-
branes, respectively [39]. These data are consistent
with the high a⁄nity Ap4A binding site on cardiac
plasma membranes not being a P2X or P1 receptor.
Our apparent Bmax value of 66 pmol mg31 for the
Ap4A receptor on cardiac plasma membranes is
within the range of receptor densities observed for
Ap4A in liver plasma membranes (47 pmol mg31)
[21]. However, the Ap4A cardiac plasma membrane
receptor density is more than three orders of magni-
tude greater than the Bmax values for the high a⁄nity
Ap4A binding site on brain synaptosomes (16 fmoles
mg31) [22]. These data suggest that there are varia-
tions of Ap4A receptor densities in di¡erent tissues.
On puri¢ed cardiac plasma membranes [K-32P]8-
N3Ap4A only photolabeled a 50 and a 30 kDa poly-
peptide (Fig. 5). Since we have previously shown that
the 30 kDa polypeptide is a consequence of artifac-
tual receptor proteolysis [26], these data are consis-
tent with Ap4A binding to a 50 kDa polypeptide on
puri¢ed cardiac plasma membranes. However, we
have also demonstrated that on isolated cardiac my-
ocytes [K-32P]8-N3Ap4A photolabeled only a 42 kDa
polypeptide [26]. We have also previously demon-
strated that the Ap4A receptor undergoes at least
two proteolytic processing steps, one of which is car-
ried out by a serine protease [1,2,23] and that this
serine protease is required for receptor activation.
Since the serine protease is separated from the plas-
ma membrane during plasma membrane puri¢cation
(unpublished observation), this suggests that the
Ap4A receptor on puri¢ed cardiac plasma mem-
branes has not been activated and that the 50 kDa
polypeptide represents the Ap4A receptor prior to
processing. The apparent Kd value for Ap4A on car-
diac plasma membranes (Table 1) is 4-fold higher
than the value obtained for activated partially puri-
¢ed cardiac membrane homogenates [2]. Although
unactivated, the higher puri¢cation of plasma mem-
branes allows for a more accurate estimation of
binding a⁄nity than studies with partially puri¢ed
membrane homogenates. This is evidenced by the
8-fold lower Kd value obtained for Ap4A with puri-
¢ed plasma membranes than the Kd value (0.65 WM)
obtained for unactivated partially puri¢ed membrane
homogenates [2]. Nevertheless, these data are consis-
tent with Ap4A interacting with a single 50 kDa
polypeptide on cardiac plasma membranes.
A number of P2Y agonists have been shown to
have varying e¡ects on Ap4A binding to membrane
receptors. The P2Y agonist ADPLS is an e¡ective
competitor of radiolabeled Ap4A binding to brain
synaptosome [22] and chroma⁄n cell P2D purinocep-
tors [38]. ATPQS is nearly as e¡ective as Ap4A at
activating cloned P2U receptors expressed in astrocy-
toma cells [40]. On the other hand Ap4A does not
compete with the P2Y agonist ATPKS binding to
brain synaptosomes [39] or liver P2Y receptors [36].
These observations suggest that classi¢cation of the
Ap4A receptor as a P2D purinoceptor should not be
accomplished by only using synthetic ATP analogs
because their speci¢city may be cell and tissue spe-
ci¢c. In addition, due to the presence of enzymes on
puri¢ed cardiac plasma membranes that rapidly hy-
drolyze ATP (Fig. 1), direct investigations of the ac-
tion of ATP is precluded. Consequently, a second
approach was required to assess the relationship of
ATP to the Ap4A receptor. This was accomplished
by photoa⁄nity labeling studies of the Ap4A recep-
tor immunoa⁄nity puri¢ed using mAb TL4. Mono-
clonal antibody TL4 has been shown to interact with
part of the Ap4A binding domain [41]. Both non-
labeled ATPQS and Ap4A were e¡ective competitors
of [K-32P]8-N3Ap4A with estimated IC50 values of 56
and 158 WM, respectively. In contrast, non-labeled
BBAMEM 77456 25-9-98
G.E. Blouse et al. / Biochimica et Biophysica Acta 1375 (1998) 61^7270
ATP was not an e¡ective inhibitor of [K-32P]8-
N3Ap4A (estimated IC50 of 2500 WM) (Fig. 7). These
data demonstrate that ATP does not bind in appre-
ciable amounts to the Ap4A receptor.
The data presented in this communication are con-
sistent with Ap4A interacting with a homogeneous
population of receptors on cardiac plasma mem-
branes and with ATP having a low a⁄nity for this
receptor. These data also support our previous ob-
servations that the cardiac Ap4A receptor is a unique
dipurinoceptor which is highly speci¢c for adenylated
dinucleotides [1,2]. However, ¢nal placement of the
cardiac Ap4A receptor as a distinct P2 purinoceptor
subclass must await the isolation and sequencing of
Ap4A receptor full length cDNA clones.
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